Phase III programme of subcutaneous concizumab prophylaxis treatment in haemophilia A and B patients regardless of inhibitor status is resumed. - Novo Nordisk

Novo Nordisk announced that the clinical trials in the concizumab phase III programme (explorer6, 7 and 8) are being resumed. The clinical trials are investigating subcutaneous concizumab prophylaxis treatment in haemophilia A and B patients regardless of inhibitor status. This follows pausing of the trials in March 2020 due to the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing phase III programme. Novo Nordisk has together with relevant authorities identified a new path forward for concizumab. New safety measures and guidelines, based on analysis of all available data, have been agreed with the FDA and the clinical hold has been lifted. In October 2019, Novo Nordisk initiated the explorer7 phase III clinical trial with concizumab in patients with haemophilia A or B with inhibitors towards FVIII or FIX. The objective of the trial is to establish the safety and efficacy of once-daily prophylactic subcutaneous concizumab delivered in a pen device to reduce the number of bleeds. A parallel phase III trial in haemophilia A or B patients without inhibitors, explorer8, was initiated in November 2019. The trials are to enrol approximately 293 patients from 32 countries. The trials were paused in March 2020..